Conflict of interest declaration: Peter Tugwell

This submission is more than 12 months old!

Updated on: 27 January 2020

Roles in: Methods Board, Co-ordinating Editors' Board, Patient Reported Outcomes Alliance, Cancer Alliance, Editorial Board

1. In the past 36 months have you accepted the following from a commercial organisation with a financial interest in any topic covered in the Cochrane Library?

a) Support for attending meetings, including sabbaticals and study tours (this covers travel, accommodation and/or hospitality)?
No

b) Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events?
No

c) Fees for organising education?
No

d) Grants and contracts?
No

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - PT is an independent committee member for a clinical trial Data Safety Monitoring Boards for FDA approved trial, funded by UCB Biopharma GmbH & SPRL and co-ordinated by Parexel International. He is an an advisory committee member of the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans.

g) Royalty or licences payments?
No

2. In the past 36 months have you, your spouse/partner or an immediate family member been employed by, or do you or they own, a commercial organization with a financial interest in any topic covered in the Cochrane Library?
No

3. Do you own stocks or shares in a commercial organization with a financial interest in any topic covered in the Cochrane Library?
No

4. Do you hold any patents (planned, issued or pending) for products relevant to any topic covered in the Cochrane Library?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - Travel and accommodation for OMERACT meetings, a registered non-profit independent medical research organization, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology, and several pharmaceutical companies listed below, which is used to support fellows, international patient groups, and support a major international bi-annual conference, which results in many peer-reviewed publications; Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, EliLilly, Genentech/Roche, Genzyme/Sanofi, Horizon Pharma Inc, Merck, Novartis, Pfizer, PPD, Quintiles, Regeneron, Savient, Takeda Pharmaceutical, UCB Group, Vertex, Forest, Bioiberica.